Adherence to guidelines and mortality in atrial fibrillation

International Journal of Cardiology

Volumn 176, Issue 2, 2014, Pages 430-436

  Díez Manglano, Jesús ^a,b,c   Gomes Martín, Javier ^a   Al Cheikh Felices, Patricia ^a   De Isasmendi Pérez, Soledad Isasi ^a   Díez Angulo, Raquel ^a   Clemente Sarasa, Carolina ^a  

^a Hospital RoyoVillanova   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Atrial fibrillation; Guidelines; Oral anticoagulants; Rate control; Rhythm control; Survival

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; DEATH; DRUG CONTRAINDICATION; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; MORTALITY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTOCOL COMPLIANCE; SURVIVAL RATE; ATRIAL FIBRILLATION; FOLLOW UP; MIDDLE AGED; STANDARDS; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MORTALITY; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES;

EID: 84922404766     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.098     Document Type: Article

References (50)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285: 2370-5.
2. Cairns J, Connolly S. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-81.
3. Wolf P, Abbott R, Kennel W. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991; 22: 983-8.
4. Aktar W, Reeves W, Movahed A. Indications for anticoagulation in atrial fibrillation. Am Fam Physician 1998; 58: 130-8.
5. Dagres N, Nieuwlaat R, Vardas P, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 2007; 49: 572-7.
6. Fang M, Singer D, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation. The AnTicoagulation and Risk factors in Atrial Fibrillation (ATRIA) Study. Circulation 2005; 112: 1687-91.
7. Hart R, Benavente O,McBride R, Perace LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999; 131: 492-501.
8. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 2008; 5: 1365-72.
9. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003; 290: 1049-56.
10. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results fromthe National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.
11. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for management of patients with atrial fibrillation: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2003 Guidelines for the Management of patients with Atrial Fibrillation. Europace 2006; 8: 651-745.
12. Snow V, Weiss KB, LeFevre M, et al. AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139: 1009-17.
13. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105: 226-38.
14. Grover S, Coupal L, Kouache M, Lowensteyn I, Marchand S, Campbell N. Estimating the benefits of patient and physician adherence to cardiovascular prevention guidelines: The MyHealthCheckup Survey. Can J Cardiol 2011; 27: 159-66.
15. Fang MC, As Go, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrage. The ATRIA (anticoagulation and risk factors in atrial fibrillation) study. J Am Coll Cardiol 2011; 58: 395-401.
16. Marcucci M, Ioroi A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med 2010; 21: 516-23.
17. Nieuwlaat R, Capucci A, Camm AJ, et al. On behalf of the Euro Heart Survey Investigators. Atrial fibrillation management: A prospective survey in ESC member countries. The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-34.
18. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE.Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-34.
19. Inoue H, Nozawa T, Okumura K, et al. Attitudes of Japanese cardiologist toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004; 68: 417-21.
20. Lin LJ, Chen MH, Lee CH, Wung DC, Cheng CL, Kao Yang YH. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-A nationwide descriptive study in Taiwan. Clin Ther 2008; 30: 1726-36.
21. Gayoso Diz P, Calle Custodio R, Prieto Maroto A, Herrera Calvo D, Sala López AI, Gómez MosqueraMD. Auricular fibrillation as a risk factor of cerebrovascular events in the over-65. Is clinical practice in anticoagulant prophylaxis adequate? Aten Primaria 2005; 36: 198-203.
22. Hansen ML, Gadsbøll N, Rasmussen S, et al. Clinical consequences of hospital variation in use of oral anticoagulant therapy after first-time admission for atrial fibrillation. J Intern Med 2009; 265: 335-44.
23. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-45.
24. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GHY. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: Implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011; 140: 911-7.
25. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: The challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006; 37: 1075-80.
26. Díez-Manglano J, Bernabeu-WittelM, Baron-Franco B, et al. En representación de los investigadores del proyecto PROFUND. Anticoagulation in polypathological patients with atrial fibrillation. Med Clin (Barc) 2013; 140: 97-103.
27. Filippi A, Zoni-Berisso M, Ermini G, et al. Stroke prophylaxis in high-risk patients with atrial fibrillation: Rhythm vs. rate control strategy. Eur J Intern Med 2013; 24: 314-7.
28. Gross CP, Vogel EW, Dhond AJ, et al. Factors influencing physician's reported use of anticoagulation therapy in nonvalvular atrial fibrillation: A cross-sectional study. Clin Ther 2003; 25: 1750-64.
29. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: Observational study. BMJ 2001; 323: 1218-22.
30. Man-Song-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation. Physicians' fears often unfounded. Arch Intern Med 2003; 163: 1580-6.
31. Aliot E, Breithardt G, Brugada J, et al. Atrial fibrillation awareness and risk education group; Atrial Fibrillation Association; European Heart Rhythm Association; Stroke Alliance for Europe; World Heart Federation. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010; 12: 626-33.
32. Piccinocchi G, LaringeM, Guillaro B, et al. Diagnosis and management of atrial fibrillation by primary care physicians in Italy. A retrospective, observational analysis. Clin Drugs Investig 2012; 32: 771-7.
33. Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: A commercial insurer perspective. J Manag Care Pharm 2013; 19: 302-16.
34. Steinberg BA, Holmes DN, Ezekowitz MD, et al. Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results of the Outcomes Registry for Better Informed Treatment of the atrial fibrillation (ORBIT-AF) registry. Am Heart J 2013; 165: 622-9.
35. Meiltz A, Zimmermanm M, Urban P, Bloch A; On behalf of the Association of Cardiologist of the Canton of Geneva. Atrial fibrillationmanagement by practice cardiologists: A prospective survey on the adherence to guidelines in the real world. Europace 2008; 10: 674-80.
36. Meinertz T, KirchW, Rosin L, Pittrow D,Willich SN, Kirchhof P. Management of atrial fibrillation by primary care physicians in Germany: Baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100: 897-905.
37. Le Heuzey JI, Breinhardt G, Camm J, et al. The RecordAF study: Design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010; 105: 687-93.
38. McCabe JM, Johnson CJ, Marcus MG. Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation. Am J Cardiol 2009; 103: 535-9.
39. Badano LP, Di Lenarda A, Bellotti P, Albanese MC, Sinagra G, Fioretti PM. Patients with chronic heart failure encountered in daily clinical practice are different from the "typical" patient enrolled in therapeutic trials. Ital Heart J 2003; 4: 84-91.
40. Taylor RS, Bethell HJN, Brodie DA. Clinical trials versus the real world: The example of cardiac rehabilitation. Br J Cardiol 2007; 14: 175-8.
41. Pereira de Sousa L, Burba J, Ruperto C, Lattuada L, Barbone F, Di Chiara A. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: Appropriateness and quality of treatment in an Italian cohort. J Cardiovasc Med (Hagerstown) 2013; 14: 534-40.
42. Modig S, Höglund P, Troein M,Midlöv P. GP's adherence to guidelines for cardiovascular disease among the elderly: A quality development study. ScientWorld J 2012. http://dx.doi.org/10.1100/2012/767892.
43. Nieuwlaat R, Olsson SB, Lip GYH, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared to undertreatment in high-risk atrial fibrillation patients. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007; 153: 1006-12.
44. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in fiver European countries: Results from the Euro Heart Survey on atrial fibrillation. Europace 2008; 10: 403-11.
45. Camm AJ, Breithardt G, Crijns H, et al. Real-life observations of clinical outcomes with rhythm-and rate-control therapies for atrial fibrillation. RECORDAF (Registry on cardiac rhythm disorders assessing the control of atrial fibrillation). J Am CollCardiol 2011; 58: 493-501.
46. Ruiz Ortiz M, Romo Peñas E, Franco ZapataM, et al. A Prospective protocol increases oral anticoagulant prescription in patients with chronic nonvalvular atrial fibrillation. Rev EspCardiol 2003; 56: 971-7.
47. Hendriks JL, Nieuwlaat R, Vrijhoef HJM, deWit R, Crijns HJGM, Tieleman RG. Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program. Neth Heart J 2010; 18: 471-7.
48. Barba Martín R, Marco Martinez J, Emilio Losa J, Canora Lebrato J, Plaza Canteli S, Zapatero Gaviría A. Two-year analysis of internal medicine activity in the National Health Care System hospitals. Rev Clin Esp 2009; 209: 459-66.
49. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-72.
50. Montes-Santiago J, Rodil V, Formiga F, Cepeda JM, Urrutia A; Working Group on Heart Failure and Atrial Fibrillation of the Spanish Society of Internal Medicine (SEMI). Features and costs of patients admitted for cardiac arrhythmias in Spain. Rev Clin Esp 2013; 213: 235-9.